Plant Name: Nama hispidum
Taxonomic Information:
Plant ID: NPO7169
Plant Latin Name: Nama hispidum
Taxonomy Genus: Nama
Taxonomy Family: Namaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| NPSR1; | |
| RECQL; TDP1; TERT; GLO1; PGD; ALOX12; AKR1B1; HSD17B2; HSD17B10; HPGD; NOX4; APEX1; POLB; | |
| ACHE; | |
| BCL2; | |
| TOP2A; | |
| TEK; INSR; MET; AXL; KDR; FLT3; CDK1; EGFR; PIM1; NUAK1; SRC; IGF1R; AURKB; CSNK2A1; | |
| CA2; CA12; CA7; CA4; | |
| TYR; | |
| KDM4E; | |
| F10; F2; | |
| AHR; | |
| FUT7; | |
| DNMT1; | |
| ABCB1; | |
| SLC22A6; | |
| LMNA; SMAD3; HSPA1A; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| DNA methyltransferase | DNMT1 | DNA (cytosine-5)-methyltransferase 1 | P26358 | CHEMBL1993 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 6.858E-09 | 2.588E-06 | AXL, EGFR, F10, INSR, MET, NOX4, SRC, TEK |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 2.493E-08 | 7.869E-06 | ABCB1, AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.235E-08 | 1.676E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.635E-07 | 3.632E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.911E-07 | 9.141E-05 | ACHE, BCL2, CDK1, CYP1A1, EGFR, F2, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 5.108E-07 | 9.426E-05 | AKR1B1, ALOX12, APEX1, CYP1A1, CYP1A2, CYP1B1, HPGD, HSD17B10, HSD17B2, KDM4E, NOX4, PGD, TYR |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.162E-07 | 1.082E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.346E-06 | 2.109E-04 | BCL2, CA2, CA7, F2, KDR, NPSR1, SRC |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.528E-06 | 2.360E-04 | EGFR, INSR, KDR |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.856E-06 | 2.750E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.179E-06 | 3.163E-04 | ABCB1, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.179E-06 | 3.163E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 2.581E-06 | 3.649E-04 | BCL2, NOX4, SRC, TERT |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.581E-06 | 3.649E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.853E-06 | 7.916E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.412E-06 | 8.453E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 7.108E-06 | 9.159E-04 | APEX1, POLB |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 9.466E-06 | 1.151E-03 | ACHE, APEX1, CSNK2A1, EGFR, FLT3, IGF1R, INSR, KDR, L3MBTL1, PIM1, SMAD3, SRC |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.036E-05 | 1.240E-03 | CA2, CA4, EGFR, HPGD, SLC22A6, TEK |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.048E-05 | 1.247E-03 | AHR, AXL, BCL2, CSNK2A1, EGFR, SRC, TOP2A |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.439E-05 | 1.640E-03 | CDK1, EGFR, IGF1R, INSR |
| BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 1.546E-05 | 1.736E-03 | CDK1, CYP1A2, EGFR, TERT |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1.682E-05 | 1.859E-03 | AKR1B1, HPGD, HSD17B10, HSD17B2, PGD |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.905E-05 | 2.043E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.129E-05 | 2.250E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.365E-05 | 2.464E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.392E-05 | 2.481E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 2.578E-05 | 2.644E-03 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 2.975E-05 | 2.985E-03 | F2, FLT3, KDR, TEK |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.137E-05 | 3.092E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.137E-05 | 3.092E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.250E-05 | 3.872E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 4.893E-05 | 4.314E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
| CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 5.090E-05 | 4.470E-03 | ACHE, AKR1B1, APEX1, CA4, EGFR, HSPA1A, NOX4, SRC, TYR |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 5.191E-05 | 4.504E-03 | AKR1B1, EGFR, HPGD, TERT |
| BP | GO:0009987; cellular process | GO:0046427; positive regulation of JAK-STAT cascade | 5.465E-05 | 4.703E-03 | AKR1B1, CYP1B1, F2, FLT3 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 5.563E-05 | 4.769E-03 | AHR, AKR1B1, APEX1, AURKB, BCL2, CDK1, CSNK2A1, DNMT1, HPGD, HSPA1A, L3MBTL1, LMNA, NUAK1, PIM1, POLB, RECQL, SMAD3, SRC, TERT, TOP2A |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 5.799E-05 | 4.952E-03 | ALOX12, CYP1B1, KDR, TEK, TERT |
| MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 6.399E-05 | 5.319E-03 | AXL, IGF1R, INSR |
| BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 7.097E-05 | 5.702E-03 | FLT3, SRC, TEK |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 7.401E-05 | 5.903E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 8.048E-05 | 6.236E-03 | ACHE, EGFR, IGF1R, INSR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.637E-05 | 6.646E-03 | AHR, CSNK2A1, KDR |
| BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1.038E-04 | 7.637E-03 | BCL2, HSPA1A, TERT |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.059E-04 | 7.695E-03 | ALOX12, HPGD |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 1.064E-04 | 7.695E-03 | BCL2, CA2, EGFR, MET, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:1900087; positive regulation of G1/S transition of mitotic cell cycle | 1.234E-04 | 8.781E-03 | APEX1, CYP1A1, TERT |
| BP | Unclassified; | GO:0006461; protein complex assembly | 1.283E-04 | 8.980E-03 | ACHE, CDK1, HSD17B10, HSPA1A, IGF1R, INSR, SLC22A6, SMAD3, SRC, TEK, TERT |
| BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 1.292E-04 | 9.016E-03 | APEX1, NOX4, TEK, TYR |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.311E-04 | 9.121E-03 | EGFR, INSR, KDR, SLC22A6, SRC, TEK |
| BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.399E-04 | 9.591E-03 | CDK1, EGFR, F2, SMAD3 |
| BP | GO:0009987; cellular process | GO:0045930; negative regulation of mitotic cell cycle | 1.464E-04 | 9.825E-03 | AURKB, BCL2, CDK1, EGFR, SMAD3, TOP2A |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.480E-04 | 9.825E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.480E-04 | 9.825E-03 | FLT3, KDR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 8.315E-10 | 1.156E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.892E-07 | 8.764E-06 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.178E-06 | 4.093E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 9.429E-08 | 6.553E-06 | CA12, CA2, CA4, CA7 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 4.583E-06 | 1.274E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.045E-06 | 1.632E-04 | INSR, BCL2, TEK, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.120E-05 | 2.224E-04 | DNMT1, ABCB1, PIM1, BCL2, CYP1B1, MET, EGFR |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.363E-05 | 2.368E-04 | SRC, KDR, BCL2, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.726E-05 | 3.445E-04 | INSR, KDR, BCL2, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.634E-05 | 3.445E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.554E-05 | 2.400E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.809E-04 | 1.934E-03 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.546E-04 | 5.139E-03 | SMAD3, FLT3, BCL2, MET, EGFR, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.530E-04 | 1.773E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.952E-04 | 3.923E-03 | SMAD3, INSR, EGFR, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 6.175E-04 | 5.365E-03 | INSR, HSPA1A, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.167E-03 | 7.676E-03 | DNMT1, FUT7, HSD17B2, CYP1A2, CYP1A1, AKR1B1, ALOX12, PGD, TYR, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 7.062E-04 | 5.694E-03 | FLT3, MET, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 7.374E-04 | 5.694E-03 | SRC, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.364E-04 | 6.119E-03 | MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.226E-03 | 7.676E-03 | HPGD, FLT3, MET, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.068E-04 | 6.302E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.872E-03 | 9.638E-03 | CSNK2A1, BCL2, CDK1, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.608E-03 | 8.660E-03 | BCL2, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.557E-03 | 8.660E-03 | SRC, CDK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.270E-03 | 7.676E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.620E-03 | 8.660E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; DNMT1; EGFR; ABCB1; |
| NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; F2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; BCL2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; TERT; AHR; SRC; BCL2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; BCL2; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; KDR; FLT3; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; KDR; EGFR; ABCB1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; TEK; EGFR; SRC; ABCB1; F2; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; F2; |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| NA: NA | Christmas disease | NA | F10; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; KDR; EGFR; AKR1B1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; BCL2; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | DNMT1; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| NA: NA | Haemophilia B | NA | F10; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; F2; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | DNMT1; EGFR; SRC; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
| NA: NA | GIST | NA | FLT3; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; EGFR; SRC; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; TERT; KDR; FLT3; INSR; EGFR; BCL2; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; FLT3; EGFR; BCL2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TERT; FLT3; DNMT1; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; F2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; F2; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; F2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; TEK; DNMT1; EGFR; SRC; ABCB1; F2; BCL2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
| NA: NA | Edema | NA | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; F2; |
| I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; F2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Soft tissue sarcoma | C00-D49 | DNMT1; |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; KDR; EGFR; TYR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; BCL2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; DNMT1; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; F2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | F2; |
| NA: NA | HIV infections | NA | AHR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
